SCALP

The Scalp Cooling Alopecia Prevention (SCALP) Trial enrolled 235 women who were diagnosed with Stage 1 or 2 breast cancer and were scheduled to receive at least four rounds of chemotherapy drugs which are known to cause hair loss and found 50.5 percent retained their hair. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.